153 related articles for article (PubMed ID: 33623790)
1. Overexpression of GSE1 Related to Trastuzumab Resistance in Gastric Cancer Cells.
Wang W; Wang S; Xu AM; Yuan X; Huang L; Li J
Biomed Res Int; 2021; 2021():8834923. PubMed ID: 33623790
[TBL] [Abstract][Full Text] [Related]
2. CMIP promotes Herceptin resistance of HER2 positive gastric cancer cells.
Xiang R; Han X; Ding K; Wu Z
Pathol Res Pract; 2020 Feb; 216(2):152776. PubMed ID: 31822364
[TBL] [Abstract][Full Text] [Related]
3. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
[TBL] [Abstract][Full Text] [Related]
4. GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis.
Ding K; Tan S; Huang X; Wang X; Li X; Fan R; Zhu Y; Lobie PE; Wang W; Wu Z
J Biol Chem; 2018 Mar; 293(11):3949-3964. PubMed ID: 29367342
[TBL] [Abstract][Full Text] [Related]
5. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
[TBL] [Abstract][Full Text] [Related]
7. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
Pietrantonio F; Fucà G; Morano F; Gloghini A; Corso S; Aprile G; Perrone F; De Vita F; Tamborini E; Tomasello G; Gualeni AV; Ongaro E; Busico A; Giommoni E; Volpi CC; Laterza MM; Corallo S; Prisciandaro M; Antista M; Pellegrinelli A; Castagnoli L; Pupa SM; Pruneri G; de Braud F; Giordano S; Cremolini C; Di Bartolomeo M
Clin Cancer Res; 2018 Mar; 24(5):1082-1089. PubMed ID: 29208673
[No Abstract] [Full Text] [Related]
9. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
[TBL] [Abstract][Full Text] [Related]
10. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer.
Wang Y; Zhao C; Chang L; Jia R; Liu R; Zhang Y; Gao X; Li J; Chen R; Xia X; Bulbul A; Husain H; Guan Y; Yi X; Xu J
EBioMedicine; 2019 May; 43():261-269. PubMed ID: 31031019
[TBL] [Abstract][Full Text] [Related]
12. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.
Shi W; Zhang G; Ma Z; Li L; Liu M; Qin L; Yu Z; Zhao L; Liu Y; Zhang X; Qin J; Ye H; Jiang X; Zhou H; Sun H; Jiao Z
Nat Commun; 2021 May; 12(1):2812. PubMed ID: 33990570
[TBL] [Abstract][Full Text] [Related]
13. Label-Free Quantitative Proteomics Combined with Biological Validation Reveals Activation of Wnt/β-Catenin Pathway Contributing to Trastuzumab Resistance in Gastric Cancer.
Liu W; Yuan J; Liu Z; Zhang J; Chang J
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29986466
[TBL] [Abstract][Full Text] [Related]
14. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
15. A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway.
Liu J; Pan C; Guo L; Wu M; Guo J; Peng S; Wu Q; Zuo Q
J Hematol Oncol; 2016 Aug; 9(1):76. PubMed ID: 27581375
[TBL] [Abstract][Full Text] [Related]
16. The Wnt3a/β-catenin/TCF7L2 signaling axis reduces the sensitivity of HER2-positive epithelial ovarian cancer to trastuzumab.
Shen G; Gao Q; Liu F; Zhang Y; Dai M; Zhao T; Cheng M; Xu T; Jin P; Yin W; Huang D; Weng H; Chen W; Ren H; Mu X; Wu X; Hu S
Biochem Biophys Res Commun; 2020 Jun; 526(3):685-691. PubMed ID: 32248976
[TBL] [Abstract][Full Text] [Related]
17. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
18. Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance.
Liu W; Chang J; Liu M; Yuan J; Zhang J; Qin J; Xia X; Wang Y
Oncotarget; 2017 Jul; 8(28):45793-45806. PubMed ID: 28507275
[TBL] [Abstract][Full Text] [Related]
19. Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer.
Sun L; Zhang J; Xu M; Zhang L; Tang Q; Chen J; Gong M; Sun S; Ge H; Wang S; Liang X; Cui L
ACS Appl Mater Interfaces; 2022 Jan; 14(1):452-463. PubMed ID: 34961307
[TBL] [Abstract][Full Text] [Related]
20. miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer.
Zhou X; Men X; Zhao R; Han J; Fan Z; Wang Y; Lv Y; Zuo J; Zhao L; Sang M; Liu XD; Shan B
Cancer Gene Ther; 2018 May; 25(3-4):68-76. PubMed ID: 29302045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
